SCHEMBL17632014

SCHEMBL17632014

N#CN1CC[C@H](C(=O)Nc2ncc(-c3ccc(F)cc3)s2)C1

nearest known ligand 0.81

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
UCHL1 P09936 3/20 0.81
USP30 Q70CQ3 14/20 0.71
MKNK1 Q9BUB5 1/20 0.53
OTUD7B Q6GQQ9 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17632018 1.00 UCHL1 (0.81) UCHL1USP30MKNK1OTUD7B
SCHEMBL29992744 0.91 UCHL1 (0.83) UCHL1USP30MKNK1OTUD7B
SCHEMBL17632501 0.91 UCHL1 (0.83) UCHL1USP30MKNK1OTUD7B
SCHEMBL17632484 0.90 UCHL1 (0.86) UCHL1USP30MKNK1
SCHEMBL17632489 0.90 UCHL1 (0.86) UCHL1USP30MKNK1
SCHEMBL17632493 0.90 UCHL1 (0.81) UCHL1USP30MKNK1OTUD7B
SCHEMBL17631832 0.90 UCHL1 (0.81) UCHL1USP30MKNK1OTUD7B
SCHEMBL17632033 0.89 UCHL1 (1.00) UCHL1USP30MKNK1OTUD7B
SCHEMBL17632038 0.89 UCHL1 (1.00) UCHL1USP30MKNK1OTUD7B
SCHEMBL23403455 0.89 UCHL1 (0.87) UCHL1USP30MKNK1OTUD7B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3828179-A1 CYANOPYRROLIDINES AS DUB MODULATORS Mission Therapeutics Limited (GB) 2021-06-02 EP claimed
EP-3197883-B1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2020-03-18 EP claimed
CN-107001339-B Novel compounds 特殊治疗有限公司 2020-03-17 CN claimed
US-10392380-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2019-08-27 US claimed
US-20180162852-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LIMITED 2018-06-14 US claimed
US-9926307-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2018-03-27 US claimed
US-20170247365-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2017-08-31 US claimed
EP-3197883-A1 NOVEL COMPOUNDS Mission Therapeutics Limited (GB) 2017-08-02 EP claimed
WO-2016046530-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2016-03-31 WO claimed
US-11993595-B2 Compounds MISSION THERAPEUTICS LIMITED (GB) 2024-05-28 US disclosed
CN-111592534-B New compounds 特殊治疗有限公司 2023-06-30 CN disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 US disclosed
US-20230052191-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2023-02-16 US disclosed
US-11472798-B2 Compounds MISSION THERAPEUTICS LTD (GB) 2022-10-18 US disclosed
US-20170247365-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2017-08-31 US disclosed
US-20170247365-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2017-08-31 US disclosed
US-20170247365-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2017-08-31 US disclosed
EP-3197883-A1 NOVEL COMPOUNDS Mission Therapeutics Limited (GB) 2017-08-02 EP disclosed
WO-2016046530-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2016-03-31 WO disclosed
WO-2016046530-A1 NOVEL COMPOUNDS MISSION THERAPEUTICS LTD (GB) 2016-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11472798-B2 Compounds UCHL1, UCHL3, UCHL5 UCHL1 1/4885USP30 20/4885MKNK1 2009/4885
US-20180162852-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 UCHL1 1/4885USP30 19/4885MKNK1 2081/4885
US-10392380-B2 Compounds UCHL1, UCHL3, UCHL5 UCHL1 1/4885USP30 20/4885MKNK1 2009/4885
US-11993595-B2 Compounds UCHL1, UCHL3, UCHL5 UCHL1 1/4885USP30 20/4885MKNK1 2009/4885
US-20170247365-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 UCHL1 1/4885USP30 19/4885MKNK1 2081/4885
US-20230052191-A1 NOVEL COMPOUNDS UCHL1, UCHL3, UCHL5 UCHL1 1/4885USP30 19/4885MKNK1 2081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.